The adoption of new, surrogate endpoints in clinical research provides a means to balance the need for timely patient access to innovative medicines without delays caused by using long-term survival endpoints with the means to measure clinical value for adjuvant and neoadjuvant therapies and allowing for the comparison of trials across multiple dimensions.
Evolving Oncology Endpoints: A New Horizon for Oncology OutcomesC T2023-02-12T05:19:19-05:00
Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.
Join experts from PHAR, Novartis, and Bausch Health for a discussion around the Delphi panels and how the results are used.
Experts will present opportunities for using agile platforms and fit-for-purpose engagement models that can drive an iterative approach to obtaining payer insights and developing impactful evidence generation strategies.